Search Results - may+khanna

7 Results Sort By:
Small Molecule Chaperones of CLN1 and CLN2
The inventors here have identified small molecules that target palmitoyl-protein thioesterase 1 (PPT1), tripeptidyl peptidase 1 (TPP1), enzymes that are deficient and less active in Batten disease or Neuronal Ceroid Lipofuscinosis. The CLN1 and CLN2 genes regulate the production of these enzymes, respectively. Background: Batten Disease, or Neural...
Published: 9/6/2022   |   Inventor(s): May Khanna, Jena Lipsa
Keywords(s):  
Category(s): Technology Classifications > Life Sciences > Small Molecules, Technology Classifications > Life Sciences > Therapeutics
Targeting CD44-Moesin Interactions with Small Molecules for Alzheimer’s Disease
This technology is a small molecule compound that could serve as a potential therapeutic for Alzheimer’s Disease (AD). The compound binds to Moesin, a protein that is associated with AD. It targets interactions between Moesin and CD44, an antigen that also has been shown to be a biomarker for AD. Targeting CD44 and Moesin interactions has proved...
Published: 8/18/2022   |   Inventor(s): May Khanna, Judith Tello Vega, Haley Williams, Vijay Gokhale, Marcel Patek, Jake Carlson
Keywords(s):  
Category(s): Technology Classifications > Life Sciences
Small Molecules Targeting Protein-RNA Interactions in ALS and Related Neurodegenerative Diseases
This invention is an in silico molecule capable of mitigating locomotor dysfunctions through TDP-43 contained RNA remodeling. Background: Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease that affects the function of nerves and muscles. In the United States over 6,000 people are diagnosed each year with an estimated 15 cases diagnosed...
Published: 7/15/2022   |   Inventor(s): Daniela Zarnescu, May Khanna, Vijay Gokhale
Keywords(s):  
Category(s): Technology Classifications > Healthcare Portfolios > Neurology, Technology Classifications > Life Sciences > Small Molecules, Technology Classifications > Life Sciences > Therapeutics
Allosteric Modulators of TDP-43 for Treating Neurodegenerative Diseases
This invention is a small molecule drug, nTRD22, that can be used to treat currently incurable neurodegenerative diseases like Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), and potentially even Alzheimer’s disease (AD) and Parkinson’s disease (PD). This molecule targets the N-terminal domain (NTD) of the DNA binding...
Published: 8/18/2022   |   Inventor(s): May Khanna, Liberty Francois-Moutal, Niloufar Mollasalehi, Vijay Gokhale, David Scott, Judith Tello Vega, Haley Williams
Keywords(s):  
Category(s): Technology Classifications > Healthcare Portfolios > Neurology > CNS & Neurosciences
Development of Aptamers Neutralizing Antibodies for Demyelinating Diseases
This innovation is research involving the development of aptamers that work to neutralize antibodies which harm the myelin sheath of nerves. The innovation can be a successful treatment for both multiple sclerosis (MS) and chronic inflammatory demyelinating polyradiculoneuropathy (CIPD). These aptamers will be very specific to block certain autoantibodies...
Published: 7/15/2022   |   Inventor(s): May Khanna, Kathleen Rodgers, Maira Soto, Niloufar Mollasalehi
Keywords(s):  
Category(s): Technology Classifications > Life Sciences > Small Molecules
Targeting TDP-43 for Parkinson's Disease Therapy
This invention is a molecule that targets the aberrant aggregation of a certain protein (TDP-43, associated with neurodegeneration) of neurons. The molecule binds to a specific site within the TDP-43 protein, and this helps prevent the unwanted aggregation of TDP-43 within neurons. The molecule has been shown to stop and even reverse neurodegeneration...
Published: 7/15/2022   |   Inventor(s): May Khanna, Liberty Francois-Moutal, Carla Koehler
Keywords(s):  
Category(s): Technology Classifications > Life Sciences > Small Molecules
New Strategies to Block RIPK1/3/MLKL-Mediated Neurodegeneration
University of Arizona researchers have discovered several small molecules that represent a new class of RIPK1/3 targeting therapeutics that can potentially be used in the treatment of Alzheimer’s Disease. These molecules inhibit necroptosis, which is a cell death pathway related to neurodegenerative diseases. Necroptosis is form of cell death...
Published: 12/1/2022   |   Inventor(s): May Khanna, Jonathan Sanchez, Vijay Gokhale, Salvatore Oddo
Keywords(s):  
Category(s): Technology Classifications > Healthcare Portfolios > Neurology, Technology Classifications > Life Sciences > Therapeutics, Technology Classifications > Life Sciences > Small Molecules